STIFEL 2026 HEALTHCARE CONFERENCE - ATRICURE INC

Explicit Guidance:

• FY2026 Revenue: Updated guidance provided for Q4 2026 is $606M–$610M, implying full-year 2026 growth of 11%–14% (accelerating from Q3 growth of 15%).
• Long-Term Targets: Maintains $750M revenue and 14% adjusted EBITDA margin targets by 2028, tracking ahead of schedule with current mid-teens growth rates.
• Gross Margins: Anticipates a near-term headwind in 2027 due to the full-year impact of a new manufacturing facility expansion (doubling capacity); expects long-term margin expansion driven by high-margin product mix (Pain Management, Encompass, Atriclip).
• Sales Force: No quantitative headcount targets, but plans to split territories and add reps incrementally to support Box X commercialization (currently ~350 US staff; ~200 Cardiac, ~40 Hybrid).

Business-Segment Outlook:

• Pain Management: Q3 growth of 33% expected to sustain. Focus on 2027 to expand customer base and drive adoption in three markets:
  • Amputations: Early stage ($1.5M Q3 run-rate), aiming for $10M+ contribution by next year.
  • Thoracic: Currently 25% penetration, targeting 2027 for continued growth via CryoMax (shorter freeze time).
  • Sternotomy: <10% penetration in ~250k procedure market; leveraging CryoMax to unlock adoption.
• LAA (Left Atrium Appendage):
  • Competitive Landscape: Acknowledges competitor (Edwards Eclipsys) presence but predicts consensus growth rates (approx. 12% for LAA US) remain accurate; headwinds limited as product penetration approaches saturation.
  • New Products: 30mm Flex Mini launching late 2026; Flex Mini V (combining FlexV efficacy with Mini profile) launching late 2027.
• Box X (Post-Op AFib):
  • Trial Status: Fully enrolled by end of 2026.
  • Data Readout: Primary endpoint (30-day post-op AFib reduction) to be presented in May 2027.
  • Impact Expectation: Projected to drive greater upside in 2027 than quality metrics; anticipated to require territory splits and incremental sales resource allocation once label obtained.
• Hybrid/PFA: Anticipates continued pressure in 2027 due to Pericardial Pacing Ablation (PFA) dominance (85-90% of ablations); no definitive "bottom" called yet.

Market and Competitive Outlook:

• Quality Metrics (STS): Phased rollout beginning 2027. Initial target of 70% patient inclusion for ablation/LAA management, rising to >90% over time.
  • Behavioral Shift: Metrics reported twice yearly at site and surgeon level; expected to drive modest ablation uptake in 2027, with significant impact by 2028–2029.
• Competitive Dynamics: Competition in LAA space viewed as "good" and validating the market; Atriclip maintains "best product" claim (smallest profile) with the only company having extensive evidence.
• Market Penetration:
  • LAA/Open Heart: Highest penetration, growth driven by new indications (Sternotomy) rather than market expansion.
  • Pain Management: Large market opportunities with low current penetration (<10-25%).

Macro / Industry Outlook:

• Clinical Evidence: Management notes physicians significantly underestimate post-op AFib rates (expect 15-20% vs. actual 35-55%); expects Box X data to correct this perception.
• Regulatory/Policy: STS quality metrics are "incredibly important"; anticipated to link to "star ratings" eventually, forcing hospital/system-wide adoption.
• Economic/M&A: No focus on external M&A or transformational deals; capital allocation focused entirely on internal reinvestment (R&D, clinical trials, new products).

Strategic Initiatives:

• Manufacturing Expansion: Doubling production capability by adding to corporate HQ; full cost impact expected in 2027, with capacity maximization lagging initially.
• Commercial Strategy: Aggressive territory splitting for Box X launch; adding clinical support to ensure "sticky adoption" of Pain Management devices (Cryo XT, CryoMax).
• Product Development:
  • 2026: Launch of 30mm Flex Mini.
  • 2027: Launch of Flex Mini V; Box X data presentation (May) and potential label expansion; continued expansion of Pain Management accounts.
• R&D Focus: Increased spend on new product development and clinical trials (LEAPS, Box X) starting now.

Risks and Headwinds to Outlook:

• Gross Margin Compression: Short-term margin pressure in 2027 due to manufacturing facility ramp-up costs.
• PFA Displacement: Continued headwinds in the Hybrid segment until PFA adoption stabilizes or converges with Atriclip's technology.
• Clinical Trial Uncertainty: Box X outcomes (May 2027) and LEAPS event rates (75% target ~2028, 100% ~2028+) are timing-dependent and could delay commercial scaling.
• Physician Behavior: Uncertainty on the speed of physician adoption regarding STS quality metrics and the magnitude of Box X data impact (minimum 10% absolute differential required to shift behavior).
• Market Saturation: LAA growth may be capped by existing high penetration levels rather than competitive loss.

Management Tone on the Future:

• Confidence Level: High confidence in "continued double-digit revenue growth" and outperformance vs. prior Long Range Plan (LRP).
• Guidance Philosophy: Explicitly cites "prudent conservatism" for Q4 guidance to ensure a pathway to meeting numbers, despite accelerating tailwinds.
• Strategic Posture: "Lean in" approach to reinvestment; willing to accept short-term margin hits (capex, R&D) to secure long-term growth drivers (Box X, Flex Mini V).
• Sentiment on Competition: Optimistic; views new entrants as validation of market size, emphasizing product superiority and evidence moat.

Miscellaneous:

• LEAPS Trial Update: Fully enrolled July 2025; 50% of events hit; 75% event target anticipated in 2028, with final 100% events likely 2028–2029 (ahead of the original 5-year plan).
• Data Granularity: STS quality metrics will be reported at both site and individual surgeon levels, allowing hospitals to identify and manage outliers.